SUMMARY OF THE INDUSTRY TASK GROUP MEETING HELD AT 08:00 ON 23 JUNE 2015 IN THE CIVITAS BUILDING
|
|
- Leslie Marcus Hudson
- 5 years ago
- Views:
Transcription
1 SUMMARY OF THE INDUSTRY TASK GROUP MEETING HELD AT 08:00 ON 23 JUNE 2015 IN THE CIVITAS BUILDING Present MRA/DoH Joey Gouws (JG) Estelle Taute (ET) Ndimuhulu Dowelani (ND) Shyamli Munbodh (SM) Jerry Molokwane (JM) Khamusi Mutoti (KhM) Hellen Moropyane (HM) Silverani Padayachee (SP) Momeena Omarjee (MO) Tohlang Sehloho (TS) Davis Mahlatji (DaM) Enos Motshitela (EnM) Griffith Molewa (GM) Kaizer Thembo (KT) Portia Nkambule (PN) Kefiloe Mompati (KeM) Industry Nicole Edelstein (NE) Norman Fels (NF) Sanjay Lakha (SL) Stavros Nicolaou (SN) Anita Smal (ASm) Hayley Eager (HE) Robyn Daniel (RD) Leigh Howes (LH) Avanthi Bester (AB) Anele Vutha (AV) Corinne Pillai (CP) Deepa Maharaj (DeM) Evelyn Mohanlall (EvM) 1. WELCOME AND APOLOGIES JG chaired the meeting and welcomed everybody to the meeting. She announced that the new Chairperson of Council, Prof Helen Rees will join the meeting later to address ITG and open communication channels to Council. NE expressed ITG s appreciation for the opportunity to meet and said it is a privilege and honour for ITG to meet and be addressed by the Chair of Council. Apologies were received from: Alice Sigobodhla, Santhani Chetty, Celecia Pleass, Abeda Williams, Judy Coates, Merle Scher, Trevor Phillips, Muhammad Bodhania, Vivian Frittelli, Nerine du Plessis, Ernest Schay, Miranda Viljoen, Lynette Terblanche, Tebogo Sebata, Robyn Howes, Tanya Vogt, Salma Ismail, Allison Vienings and Wayne Robinson. 2. APPROVAL OF THE MINUTES OF THE MEETING HELD ON 17 MARCH 2015 The minutes of the meeting held on 17 March 2015 were accepted as an accurate reflection of the meeting. ET proposed RD seconded 3. MATTERS ARISING AND FEEDBACK 3.1. Medicines Evaluation & Research Pre-registration unit DaM reported that the revised Biostudies and Dissolution guidelines were ratified by Council and will be published on the website for implementation. - Revised Biostudies and Dissolution guidelines to be published for implementation Post-registration unit RD asked for confirmation that dossiers converted to CTD should only be submitted when next submitting Type B or C amendments in view of the deadline for conversion of all dossiers to CTD format coming closer. ET confirmed that converted dossiers should only be submitted when there is an amendment for the relevant dossier. The unit is busy evaluating amendments from January 2014, but there are still a lot from December There are still a large number of urgent amendment requests jumping the queue for priority and tender products and not enough progress is therefore made with routine submissions. Page 1 of 7
2 Guidelines under review: - The Post-importation testing guideline will be published for comment. - The Labelling of medicines containing sugars guideline is being finalised and will be published shortly. - Progress has been made in terms of the revision of the requirements for Section 3.2.S in the P&A guideline. Information was obtained from other regulators at the IGDRP meeting that was hosted in South Africa in May. The information has been circulated to the P&A Committee. The revision of the guideline will now be finalised and it will then be ready for comment. - The revision of the Amendments guideline will follow once the revision of the P&A guideline has been finalised. JG reported that MCC is looking at initiatives to ensure that the regulatory requirements for generic medicines are aligned with international requirements to enable faster registration timelines. One of these is the International Generic Drug Regulators Programme (IGDRP). SP provided an overview of the IGDRP. The IGDRP was formed to allow information and work sharing. Some of the regulators include those from Canada, Australia, EU, UK, Singapore, Switzerland and Chinese Taipei. EDQM and WHO participate as observers. Information is e.g. shared around the requirements for Active Substance Master Files (ASMF), bioequivalence and biowaivers. An information sharing pilot project was initiated last year. The EU Decentralised or Centralised Procedure (DCP or CP) will be used as a model to share information with authorities from Australia, Canada, Switzerland and Chinese Taipei during the scientific assessment phases of the DCP/CP. South Africa wishes to engage but a full review of the ASMF in terms of the restricted part is not done and the reports on the evaluation of the FPP are not detailed enough to share. Information can however be accessed from other IGDRP regulators. The EDQM is e.g. sharing information on ASMFs in terms of major deficiencies identified and GMP status of the API manufacturers. WHO prequalified APIs are already being accepted by MCC. The next IGDRP meeting will take place in South Korea. IGDRP launched a website where more information can be found: - The revised Post-importation testing guideline to be published for comment. - The revised Labelling of medicines containing sugars guidelines to be finalised and published for implementation Biological medicines KM reported that a communication will be sent to industry regarding vaccines and that a roundtable meeting is planned to discuss the annual strain update CAMs Refer to point Veterinary Medicines Comments from SAAHA on the Veterinary antimastitis medicines guideline will be discussed at the next Veterinary Committee meeting. HE asked if there was any feedback in terms of the request from SAAHA that veterinary CAMs products be submitted under Act 36 and not Act 101. JG asked that the request should be submitted via the Registrar s office and recommended that the request for Section 36 exemption should include a clear motivation why the products should be regulated under Act 36. HE asked if any tentative dates have been made available for a P&A workshop for applicants with veterinary medicines. It was confirmed that no dates were finalised yet and these will be made available to SAAHA. Page 2 of 7
3 - SAAHA to submit a request via the Registrar s office that veterinary CAMs products are submitted under Act 36 and not Act A date for a P&A workshop for applicants with veterinary medicines should be set Clinical evaluation & trials Clinical trials The dedicated central process will be published later in the week. The Risk-based monitoring guideline will be published for comment. The dispensing by healthcare professionals during clinical trials policy is still being discussed at Committee level. LH said that recent recommendations required the license and conditions for cold storage for shipping and warehousing of investigational products and asked if this will be required in all submissions in future. PN replied that each application is reviewed on its own merits. The Committee is working on policy documents that will cover all issues that have been identified, e.g. laboratory competence and providing accreditation certificates. LH mentioned that observational studies were previously submitted for notification and not approval. Approval letters are now being received. PN replied that the Committee reviews whatever is submitted to them, especially Phase IV studies. It is often found that some of these are not pure Phase IV studies; the comparator product might e.g. not be registered in South Africa. Acknowledgement letters and not approval letters are issued for true Phase IV studies. JG reported that it is increasingly found that a site doesn t have an emergency trolley during GCP inspections. She asked that all clinical trial sites must be reminded that they must have an emergency trolley relevant to the specific study being conducted. If these sites are not compliant, they will not be approved. The clinical trial SAE guideline is in the final stages of discussion and the aim is to table it at the next Council meeting. - Dedicated central addresses and processes to be followed to be published. - Risk-based monitoring guideline to be published for comment. - Dispensing by healthcare professionals during clinical trials policy to be finalised. - ITG to remind all investigators that they must have an emergency trolley relevant to the specific study being conducted. - Clinical trial SAE guideline to be finalised and tabled at Council Pre-registration clinical evaluation Interviews are underway to appoint three internal evaluators to improve turnaround times. ET advised that the annotated PI and PIL should be submitted in Section and the clean PI and PIL in Section 1.3 when submitting responses to pre-registration clinical recommendations Post-registration clinical evaluation HM reported that a formal response is still being prepared regarding the ITG letter expressing concern regarding the strict implementation of the SR-PINs guideline and the response will be finalised and sent out soon. The Clinical Unit will do a presentation at the July SAPRAA meeting on the Regulation 9 and 10 process. Questions should be sent to the unit before the meeting to ensure that they will be addressed. The standardised text to be included for ARBs and ACE inhibitors has been updated and will be published for implementation. Page 3 of 7
4 HM asked applicants to comply with the following: - Applicants should not submit double sided copies when submitting clinical responses. - The approved PI and PIL must be included in Sections and respectively when submitting amendments. - All changes to the approved text should be indicated by underlining for additions, strike through for deletions and broken underlining for re-wording in the annotated PI submitted in Section A copy of the latest innovator PI must be included in applications for generic medicines. Applicants sometimes include a foreign SPC for the innovator, but a copy of the local innovator PI must always be included. - The three copies of amendment submissions must be submitted as three separate copies/volumes and not all bound into one volume. NE queried the status of the backlog in terms of evaluation of safety updates. HM replied that they have nearly completed all 2011 submissions and are busy with submissions up to May The unit is trying to allocate newer and older submissions for the same product to the same evaluator. In this regard it is important to state in new submissions that previous submissions are still pending and to include clear cross-references to the previous submissions. - Response will be sent to ITG regarding the concerns expressed in terms of the implementation of the SR-PINs guideline Pharmacovigilance PN reported that the Post-marketing ADR guideline will be published for comment this week. DHCPLs it was confirmed that DHCPLs should be distributed via surface mail, and distribution via can be added. The guideline on Risk Management Plans (RMPs) is still under discussion by the PV committee. JG informed the meeting that a lot of work is being done in the PV unit including initiatives to sensitise reporting and to include vigilance for medical devices and CAMs. The unit is also working more closely with the WHO and is investigating implementation of the WHO VigiFlow programme which already makes provision for herbal medicines and CAMs. SL asked for clarification regarding the requirements for annual summary reports as some applicants are asked to submit reports and others are told not to submit. PN replied that the revised Post-marketing ADR guideline will address the requirements. - Post-marketing ADR guideline to be published for comment Section 21 SM reported that the Section 21 guideline was tabled at Council and that it was referred back for further input and to align requirements with those of other stringent regulatory authorities. The guideline will cover all unregistered allopathic medicines and CAMs. The revised guideline will be tabled again at the next Council meeting. JG asked that the GMP status of the manufacturing facility should be included in the application for Section 21 approval for unregistered products. The emergency after hours phone number is The treating physician must phone and verbal authorisation will be followed-up with written authorisation the next day. When emergency authorisation for named patients is required over a weekend, the documentation must be submitted in writing and telephonic approval will be given. - Section 21 guideline to be finalised and published for comment. Page 4 of 7
5 3.3. Inspectorate & Law Enforcement Inspectorate unit Comments were received from most wholesalers on the Guideline for Wholesalers to Export Medicines. Not many comments were received from applicants. The guideline will be finalised and tabled at Council. A workshop will be arranged on the requirements as there appears to be confusion between commercial ownership (when the wholesaler buys and owns the product) and regulatory ownership. Applicants must know when their products are exported. The GWP guideline is on hold until the matters around exporting of medicines have been sorted out. Applicants are reminded that a hard copy of SMFs must be submitted, together with an electronic copy on CD-ROM. The guideline on how Inspection Reports should be responded to was discussed at Council and will be published. Requirements will be similar to those of the TGA and MHRA to ensure responses are prepared and submitted in a standardised manner. A workshop will be arranged with CAMs manufacturers regarding GMP standards in August Expectations from the regulator and industry challenges will be discussed with the view to develop a clear roadmap on how and by when the CAMs manufacturers will need to comply with GMP standards. Applicants must submit full motivations with valid reasons for requests for once-off approvals in the case of shortages of medicines. Each application is evaluated on its own merits. Inspections are planned in Serbia and Turkey in July. Inspection trips are planned to India, Mexico and Brazil in the rest of the year. EnM and JG explained that international inspections are planned based on applications received. New sites and sites that previously had a negative GMP status are prioritised. Trips are usually planned for a month to specific countries or regions. Once approval is received for a trip, the plan to the various sites to be inspected within the region is finalised. SL asked if a letter can be issued by the Inspectorate for type C amendments, once they have finalised their part of the evaluation. EnM replied that it is being considered but they have a challenge in terms of capacity. Four administrative assistants are being recruited to provide assistance. Fast tracking of certain processes is also being investigated to speed up issuing of amended registration certificates. JM and JG informed the meeting that API manufacturers will be inspected in future and API manufacturers in South Africa will be licensed. A guideline on API GMP requirements will be implemented. - Workshop to be arranged regarding the Guideline for Wholesalers to Export Medicines, and guideline to be finalised and tabled at Council. - The guideline on how to respond to inspection reports will be published. - Workshop on GMP standards to be arranged with CAMs manufacturers Licensing unit RD reported that ITG is working on various options for a central repository for PIs. Once a proposal is ready, an appointment will be made to discuss the proposal and way forward. - ITG to share proposal regarding the central PI repository with the N&S Committee once finalised Law Enforcement Autogenous vaccines and compounding of veterinary products are still being discussed Operations & Administration Retention fees are being complicated by applicants who are paying retention fees as per the new fees that were published for comment. ET asked that applicants should please pay the fees as per the reminder letter that was sent out. Where incorrect fees were paid, arrangements must be made to refund the entire amount, and a new payment made for the correct amount. Applicants should also please pay attention to submit proof of payment with a cover letter with AFJ as the working code. Page 5 of 7
6 NE queried the status of the new proposed fees. JG replied that only 1 comment had been received that indicated acceptance of the fees. The Minister of Health will be requested to publish the new fees for implementation in July Routine post-screening submissions submitted January to March 2012 are currently being allocated for evaluation. The fast-track submissions and submissions for priority diseases are taken out of the routine queue and allocated for review depending on availability of the relevant expert evaluators. NB: Industry is again requested not to follow-up on products submitted (postscreening) after January to March 2012, unless these were approved for fasttrack evaluation. Screening outcome letters are being sent for products up to July If screening outcomes have not been received for products submitted prior to July 2014, applicants can follow up on these with Santhani Chetty. ET reported that a new MCC website is being developed. The development is being done in stages. In the first phase the current content will be transferred. The content will be searchable and there will be an option to download or documents. The website will be more secure and user friendly. The target is to launch this stage by end July In the next stage an interactive part will be developed for Module and will eventually link to the EDMS and ectd. Going live with ectd is delayed due to the lack of IT infrastructure and is not dependent on registration of all the products in the pilot project. The guidelines, validation criteria, specifications and DTD will be revised taking all the learnings in the pilot project into account. A workshop will be arranged with Industry. SL asked if there was any feedback to the letter sent by ITG to request that submission of modules 4 and 5 be allowed in electronic format and that the requirements be clarified in the guidelines as an interim measure due to the delay in the rollout of the ectd. ET replied that guidelines cannot be amended for interim measures. Requests can be submitted to Ops & Admin and will be reviewed case by case. Applicants must take responsibility and know what they are submitting. The size of a submission can be reduced significantly if care is taken to remove all the raw data. Paper copies are still required for evaluators until ectd is rolled out. The electronic copy, if agreed to, will be kept as the file copy with the proviso that paper copies have to be submitted on request. 4. ADDRESS BY CHAIR OF MCC, PROF HELEN REES JG welcomed and introduced the Chair of MCC, Prof Helen Rees (HR). HR said the Minister of Health asked her to chair Council and to steer the course towards SAHPRA. The new MCC was appointed and had their first meetings. Some Council members stayed on and there are some new members bringing new expertise to Council. There is a lot of energy in MCC and recognition that things can be done better. Issues such as the backlog and other matters holding industry back will be addressed. HR acknowledged that there is a need for better communication and wants to create forums for communication and set up a communications group for the secretariat. Working groups are being set up to look at how things can be done differently and to address new issues, e.g. CAMs, medical devices. The intention is to find novel and innovative ways of addressing all the issues, including the backlog, while maintaining the mandate of the MCC. SN welcomed HR back and cautioned that the expectation in terms of the transition from MCC to SAHPRA must be calibrated realistically especially in terms of human resources and asked how industry can become involved. He mentioned that the public health enhancement fund social compact could perhaps be used to bolster funds for human resources. He commended Council for their willingness to engage transparently and openly and pleaded for collaborative engagement with Council going forward. NF said industry is seeking clarity in terms of the regulatory dilemma regarding CAMs. He asked when the Regulations of 2013 will be rescinded and new Regulations published incorporating e.g. the Health Canada monographs. Page 6 of 7
7 HR responded that one of the biggest hindrances is human resource capacity. Consultants were hired in the past and some progress was made but things slipped back again. It is important to build sustainable capacity. International donors are willing to assist. A short course in regulatory sciences training is already being set up in collaboration with the University of the North West. The Institute for Regulatory Science is seriously being looked at. International funding has been obtained and the intention is to build up regional capacity keeping an eye on harmonisation. The availability of funds from industry is noted and a motivation will be taken back to the DG and Minister of Health to make use of the funds. Sustainable funding must be obtained to appoint more staff. Consultants is not the way to go, SAHPRA must become self-sustaining. JG added that 52 posts have been advertised since November and interviews and recruitment are ongoing for administrative and technical staff. JG said the CAMs Regulations are being discussed. The definition will be changed taking industry proposals into account. Labelling requirements for CAMs were tweaked end They have listened to stakeholders and spoken to other regulators that are regulating CAMs. A team was sent to Health Canada to look at their framework and how they evaluate CAMs. TGA and MHRA processes were also evaluated. The TGA said they will also be changing their requirements to be more in line with those of Health Canada and the MHRA. The information brought back from Health Canada and the MHRA was workshopped by the Complementary Medicines Committee (CMC) and secretariat in November. The guidelines are being redrafted taking the information obtained from other regulators into account. Frequent meetings are being held and the plan is to table the first guideline documents at the August Council meeting and then publish them for comment. NF welcomed the feedback and said industry want to work together and be part of the solution. NE said a Specialist Committee was formed in ITG to deal with CAMs related matters and asked what industry could do to assist going forward. JG said the CMC and CAMs unit have put in a huge effort to move forward since the new MCC was appointed. The revised guidelines will be published and industry will then be invited to a workshop. NE asked if the list of queries and points requiring clarification that have been identified by industry should be submitted in the interim. JG and KT asked that the queries be submitted as soon as possible. The CMC and CAMs unit could then try to address the issues before the revised guidelines are finalised. JG informed the meeting that the Medical Devices Regulations will be published soon for a one month comment period. HR concluded that MCC members are committed to push forward and prepare for the transition to SAHPRA while keeping up with the day to day activities of Council. A new committee has been established that will meet after the ITG meeting to tackle the backlog issue and put a timeframe, vision and strategy in place to deal with the backlog. 5. MEETING DATES FOR THE REST OF 2015 The meeting dates for the rest of 2015 are 18 August & 10 November. 6. CLOSURE JG closed the meeting and asked that the burning issues that were not addressed should be sent to her via . HR committed to try and join future meetings. NE thanked JG for the meeting and HR for attending on behalf of ITG. The meeting closed at 10:10. Page 7 of 7
SUMMARY OF THE INDUSTRY TASK GROUP MEETING HELD AT 09:00 ON 17 MARCH 2015 AT THE CIVITAS BUILDING
SUMMARY OF THE INDUSTRY TASK GROUP MEETING HELD AT 09:00 ON 17 MARCH 2015 AT THE CIVITAS BUILDING Present MRA/DoH Alice Sigobodhla (ASi) Estelle Taute (ET) Ndimuhulu Dowelani (ND) Shyamli Munbodh (SM)
More informationLEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS
LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS Joey Gouws MCC and Cluster: Food Control, Pharmaceutical Trade and Product Regulation NATIONAL DEPARTMENT OF HEALTH
More informationThe place of the Certification procedure in 2017 in the EU regulatory framework and beyond. Prague, 19 September 2017
The place of the Certification procedure in 2017 in the EU regulatory framework and beyond Prague, 19 September 2017 Hélène BRUGUERA Head of the Certification Department, EDQM, Council of Europe CEPs in
More informationUPDATE: Regulatory Framework for Medical Devices in South Africa. SAMED Annual Conference. 14 June 2018 Jerry Molokwane
UPDATE: Regulatory Framework for Medical Devices in South Africa SAMED Annual Conference 14 June 2018 Jerry Molokwane Medicines and Related Substances Act, 1965 (Act 101 of 1965) Act 72 of 2008 and Act
More informationFeedback on SADC Workshop of Industry & Regulators. Luther Gwaza PhD Consultant
Feedback on SADC Workshop of Industry & Regulators Luther Gwaza PhD Consultant SADC WORKSHOP ON REGISTRATION OF MEDICINES & GOOD MANUFACTURING PRACTICE STANDARDS 11 TH 13 TH APRIL 2016, SOUTH AFRICA Brief
More informationICH Regulators Forum. Dr Peter Arlett EU
Dr Peter Arlett EU International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use In this presentation ICH Regulators Forum: Background ICH Regulators
More informationTrends in the development of regulatory systems by the example of ICH countries
Trends in the development of regulatory systems by the example of ICH countries Author: Pär Tellner, Member of ICH Management Committee (ICH MC), EFPIA * Date: 27/08/2018 * GMP conference, Kazan, Russia
More informationAnnex 2 to the HMA esubmission Roadmap: Implementation of mandatory use of ectd format for regulatory submissions
10 March 2017 Annex 2 to the HMA esubmission Roadmap: Implementation of mandatory use of ectd format for regulatory submissions Status: Final updated version adopted by the esubmission CMB Scope This annex
More information1 The EU Harmonised technical ectd guidance version 4.0
Annex 2 to the HMA esubmission Roadmap: Implementation of mandatory ectd format for regulatory submissions (Status: Final version adopted by the esubmission CMB. Dated 26 July 2016) Scope This annex is
More informationSADC Collaborative Medicines Registration Initiative (Zazibona)
SADC Collaborative Medicines Registration Initiative (Zazibona) Dr Sinah Selelo Drugs Regulatory Unit Ministry of Health & Wellness GALVmed/OIE stakeholder workshop on the harmonisation of the registration
More informationEDQM roadmap for electronic submissions
EDQM roadmap for electronic submissions Cornelia Bigler Weber scientific assistant Certification Department, EDQM 19 September 2017 1 Agenda esubmissions Roadmap for CEP applications with its major changes
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL GUIDELINES FOR RECALL/ WITHDRAWAL OF MEDICINES This document has been prepared to serve as a recommendation to applicants regarding the recalls of medicines, and the Medicines
More informationAdopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014
21 March 2014 EMA/INS/PhV/192231/2014 Union procedure on the management of pharmacovigilance inspection findings which may impact the robustness of the benefit-risk profile of the concerned medicinal Adopted
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationSADC Collaborative Medicines Registration Process (ZAZIBONA) Farai Masekela 13 April 2016
SADC Collaborative Medicines Registration Process (ZAZIBONA) Farai Masekela 13 April 2016 Presentation Outline Brief Background Terms of Reference Objectives of the Collaborative procedure Progress ZAZIBONA
More informationICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY
ICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY 1. Opening Discussions The ICH Steering Committee (SC) meeting was chaired by the FDA. The meeting commenced with the provision of
More informationWork plan for GCP Inspectors Working Group for 2018
22 March 2018 EMA/87812 /2018 Committees and Inspections Chairperson: Ana Rodriguez The activities outlined in the work plan for 2018 have been agreed in view of preparation for the Agency s relocation
More informationSafeguarding public health. The New PV Legislation. Perspective from a Member State
Safeguarding public health The New PV Legislation Perspective from a Member State Mick Foy Reinforcing patient safety in Europe, Zagreb June 2011 Content Background The new EU PV Package ADR Definition
More informationTrial Management: Trial Master Files and Investigator Site Files
Title: Outcome Statement: Written By: Trial Management: Trial Master Files and Investigator Site Files Staff working on research studies in NSFT will be informed about the requirements of setting up and
More information...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS
...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS 1 Table of Contents Pg 3 Pg 4 Pg 5 About Ivowen Limited Meet the team Pharmaceutical Regulatory Affairs Services: Human & Veterinary Pg 5 Pg 5 National Procedures
More informationReflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP Compliance Problems. Outcome of 10 September 2012 Workshop
Reflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP Compliance Problems Outcome of 10 September 2012 Workshop Management Board Meeting - Agenda Point B10 04 October 2012
More informationOverview of ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
Overview of ICH June 2018 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH Legal notice Legal Notice This presentation is protected by copyright and
More informationReport on SAPC HOPS Meeting 5 April The SAPC met with Heads of Pharmaceutical Services from both the public and private sectors.
Report on SAPC HOPS Meeting 5 April 2018 The SAPC met with Heads of Pharmaceutical Services from both the public and private sectors. 1. LEGAL SERVICES AND PROFESSIONAL CONDUCT Good Pharmacy Practice rules
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL QUESTIONS & ANSWERS: LICENSING OF MEDICAL DEVICE ESTABLISHMENTS This document is intended to provide clarity on guidelines and applications for the licensing of medical device
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 26 July 2012 EMA/118465/2012 3 4 Guideline on good pharmacovigilance practices (GVP) Module XV Safety communication 5 Draft finalised by the Agency in collaboration with Member States and submitted
More information9/10/2013. Contributions of ECHA to the achievement of the REACH goals. Content of Discussion
Contributions of ECHA to the achievement of the REACH goals 5 Jahre REACH und weitere Beitrage zur Nachhaltigen Chemie Darmstadt, Germany 4 September 2013 Geert Dancet Executive Director Content of Discussion
More informationGood Pharmacovigilance Practice. Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA
Good Pharmacovigilance Practice Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA Content ADR Reporting Definition & Increased scope Transition arrangements
More informationTake a Course of Action.
Take a Course of Action. When you choose RAPS Online University, you ll be on track to expand your regulatory knowledge and advance your career. Our comprehensive learning provides an immersive experience
More informationRole and Vision of PMDA
Role and Vision of PMDA ~Promoting Global Public Health~ Taisuke Hojo Senior Executive Director Pharmaceutical and Medical Devices Agency (PMDA) 1 st Malaysia-Japan Symposium March 10 th, 2015 Today s
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL SA GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINES This document is intended to serve as guidance on the requirements for Good Manufacturing Practice in South Africa. This
More informationThe New EU PV Legislation: View from the European Commission
The New EU PV Legislation: View from the European Commission International seminar 26 May 2011 Lenita LINDSTRÖM Senior Policy Officer Pharmaceuticals Unit/DG SANCO Rationale for the revision Calls for
More informationSafeguarding public health. The New PV Legislation its Impact on PV & MI
Safeguarding public health The New PV Legislation its Impact on PV & MI Sarah Vaughan - MHRA PIPA 2013 Manager s Meeting 13 th February 2013 Content Scope of change Key areas - ADR reporting - DDPS to
More informationKeele Clinical Trials Unit
Keele Clinical Trials Unit Standard Operating Procedure (SOP) Summary Box Title SOP Index Number SOP 21 Version 4.0 Approval Date Effective Date Non-Compliance: Deviations and Serious Breaches of GCP and/or
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 2017 EMA/118465/2012 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module XV Safety communication (Rev 1) Date for coming into effect of first version 24 January 2013 Draft
More informationREPORT ON DRUG REGULATORY SYSTEM ASSESSMENT OF MONGOLIA
REPORT ON DRUG REGULATORY SYSTEM ASSESSMENT OF MONGOLIA ULAANBAATAR 2011 Abbreviations... 3 Acknowledgement... 4 Executive Summary... 5 1. General information on the assessment.... 7 1.1 Purpose of this
More informationLegislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018
Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018 Dr. Rania Bader, HRH2030 Health Workforce Competency Lead HRH2030 The Human Resources for Health (HRH2030) is a
More informationBEST PRACTICE GUIDE FOR DECENTRALISED AND MUTUAL RECOGNITION PROCEDURES
BEST PRACTICE GUIDE FOR DECENTRALISED AND MUTUAL RECOGNITION PROCEDURES Doc. Ref.: CMDh/068/1996/Rev.10 April 2013 INTRODUCTION 1. Competent authorities should ensure that their assessment reports are
More informationRegulatory Conference: KEY TAKE- AWAYS. Engela Dedwith, Eli Lilly
2 nd African Regulatory Conference: KEY TAKE- AWAYS Engela Dedwith, Eli Lilly CONFERENCE TOPICS 1. Regulatory Harmonisation 2. The Global Regulatory Environment 3. The Value of Research and Development
More informationGUIDELINES ON PROCEDURAL ASPECTS FOR APPLICATIONS FOR MARKETING AUTHORIZATION OF MEDICINAL PRODUCTS
Doc. No. TFDA/DMC/MCER/---- TANZANIA FOOD AND DRUGS AUTHORITY GUIDELINES ON PROCEDURAL ASPECTS FOR APPLICATIONS FOR MARKETING AUTHORIZATION OF MEDICINAL PRODUCTS (Made under Section 52 (1) of the Tanzania
More informationStandard Operating Procedure. Essential Documents: Setting Up a Trial Master File. SOP effective: 19 February 2016 Review date: 19 February 2018
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-06-003 Essential Documents: Setting Up a Trial Master File SOP effective: 19 February 2016 Review date: 19 February 2018 SOP author signature:
More informationFrequently Asked Questions. The CIRB is located at 168 Jalan Bukit Merah #06-08 Tower 3 Connection One Singapore
1. Where is the location of the CIRB? The CIRB is located at 168 Jalan Bukit Merah #06-08 Tower 3 Connection One Singapore 150168. 2. When is the submission deadline? The CIRB meets once a month. The submission
More informationBETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS
A2 BETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS March 2012 A3 BETTER REGULATION OF MEDICINES INITIATIVE (BROMI) FIFTH REPORT ON PROGRESS Chief Executive s foreword In January
More informationREGISTRATION OF MEDICINES IN THE EURASIAN ECONOMIC UNION
REGISTRATION OF MEDICINES IN THE EURASIAN ECONOMIC UNION www.gratanet.com At the Pharmaceutical Forum of the EAEU and CIS countries held in Moscow in late February 2018, the Director of the Department
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Routine Project Audit SOP Number: 6 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date: August
More informationCMDv/BPG/002. BEST PRACTICE GUIDE for Veterinary Decentralised Procedure (DCP)
BEST PRACTICE GUIDE for Veterinary Decentralised Procedure (DCP) Edition number: 05 Edition date: 7 November 2013 Implementation date: 6 February 2006 CMDv Secretariat: 7 Westferry Circus, Canary Wharf,
More informationCertification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit
Certification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit 01 Training package Why is training needed? Training modules CPP overview CPP scenario training
More informationSponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law
EU Directives Pharmacovigilance Legislation, SOPs and Reporting Louise Boldy, Governance & Safety Manager David Martin, Pharmacovigilance Monitor EU Legislation 2001/20/EC 2005/28/EC EudraLex Vol 10 UK
More informationResearch Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004
Title: Outcome Statement: Research Auditing and Monitoring Procedures Researchers in the Trust and research partners will be informed about the requirements and procedures involved in research audit and
More informationesubmission roadmap v2.0: Industry viewpoint
TOPRA Veterinary Medicines Symposium 2017 esubmission roadmap v2.0: Industry viewpoint Patrizia Oelker Boehringer Ingelheim Animal Health ENABLING AND PROMOTING EXCELLENCE IN THE HEALTHCARE REGULATORY
More informationSTANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager
STANDARD OPERATING PROCEDURE SOP 710 Good Clinical Practice AUDIT AND INSPECTION Version 1.3 Version date 27.02.2018 Effective date 3.03.2018 Number of pages 10 Review date February 2020 Author Role Approved
More informationDocument Title: Study Data SOP (CRFs and Source Data)
Document Title: Study Data SOP (CRFs and Source Data) Document Number: SOP047 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationCorporate. Research Governance Policy. Document Control Summary
Corporate Research Governance Policy Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date: Review Date:
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL GUIDELINE FOR RECALL / WITHDRAWAL OF MEDICINES, MEDICAL DEVICES AND IVDs This document has been prepared to serve as a recommendation to applicants regarding the recalls of medicines/medical
More informationASSESSMENT OF THE CONSOLIDATED ANNUAL ACTIVITY REPORT OF THE AUTHORISING OFFICER FOR THE YEAR 2014
Management Board Decision 07/2015 1(5) ASSESSMENT OF THE CONSOLIDATED ANNUAL ACTIVITY REPORT OF THE AUTHORISING OFFICER FOR THE YEAR 2014 THE MANAGEMENT BOARD, Having regard to Regulation (EC) No 1907/2006
More informationGuidance notes for patient safety and pharmacovigilance in patient support programmes
Guidance notes for patient safety and pharmacovigilance in patient support programmes Authors: The ABPI Pharmacovigilance Expert Network Version: 2.14 Date: March 2018 Acknowledgements: We thank the many
More informationQuality Assurance in Clinical Research at RM/ICR. GCP Compliance Team, Clinical R&D
Quality Assurance in Clinical Research at RM/ICR GCP Compliance Team, Clinical R&D Slide 1 of 13 What is Quality Assurance? The maintenance of a desired level of quality in a service or product, especially
More informationConsideration on Global Harmonization
ICDRA Workshop I Consideration on Global Harmonization Oct. 25, 2012 Dr. Nobumasa Nakashima Director, Office of International Programs PMDA, Japan 1 Current Harmonization Activities ICH: International
More informationNAMIBIA MEDICINES REGULATORY COUNCIL MINISTRY OF HEALTH AND SOCIAL SERVICES
1 NAMIBIA MEDICINES REGULATORY COUNCIL MINISTRY OF HEALTH AND SOCIAL SERVICES FEES PAYABLE TO THE REGISTRAR (Regulation 47) 1. In respect of an application for registration of a Category A medicine - (a)
More informationReconfirmation_SOP. - If the letter states that they were. Description/ Scope:
_SOP Standard Operating Procedure on the reconfirmation of officially recognised disease status and of the endorsement of national official control programmes of Member Countries Description/ Scope: This
More informationCLP the implementation of GHS in the EU Facts and practical advice
CLP the implementation of GHS in the EU Facts and practical advice Seminar on the latest trend regarding revised CSCL, REACH and CLP 30 March 2010, Tokyo Gabriele Schöning ECHA Classification Unit Content
More informationEffective Date: 11/09 Policy Chronicle:
Title: Investigational Drug Service Functions Policy Type: Clinical Operations Replaces (supersedes): Title: N/A Policy Chronicle: Date Original Version of Policy was Effective: 09/06 Reviewer Signature:
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More informationGCP INSPECTORATE GCP INSPECTIONS METRICS REPORT
GCP INSPECTORATE GCP INSPECTIONS METRICS REPORT METRICS PERIOD: 1 st April 1 to 31 st March 11 DATE OF ISSUE: 1 th March 1 MHRA Central Region Medicines Inspectorate Falcon Way, Shire Park Welwyn Garden
More informationNotice. Revised Draft Guidance Document: Preparation of Drug Submissions and Applications in the Common Technical Document (CTD) Format
August 8, 2011 Notice Our file number: 11-113839-2 Re: Revised Draft Guidance Document: Preparation of Drug Submissions and Applications in the Common Technical Document (CTD) Format Health Canada is pleased
More informationPost Market Surveillance Requirements. SAMED Regulatory Conference 2 December 2015
Post Market Surveillance Requirements SAMED Regulatory Conference 2 December 2015 Topics Surveillance & Vigilance Adverse Events Reportable Adverse Events Reporting Adverse Events Time frames Exemptions
More informationNEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use EMEA/267187/2005/ Rev. 1 London, 26 April 2006 NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE The CPMP/CHMP
More informationGovernance %%.4- r2&% Queen s University Belfast. Standard Operating Procedure Research Governance. r2.aoc7. Research and Enterprise
Queen s University Belfast Research and Enterprise Standard Operating Procedure Research Governance Title: Delegation of Responsibilities SOP Reference QUB-ADRE-005 Date prepared 23 June 2008 Number: Version
More informationCorporate Induction: Part 2
Corporate Induction: Part 2 Identification of preventable Adverse Drug Reactions from a regulatory perspective March 1 st 2013, EMA Workshop on Medication Errors Presented by Almath Spooner, Pharmacovigilance
More informationLegal limitations for nurse prescribers: a focus on dispensing. Andy Gray Division of Pharmacology Discipline of Pharmaceutical Sciences
Legal limitations for nurse prescribers: a focus on dispensing Andy Gray Division of Pharmacology Discipline of Pharmaceutical Sciences Outline What is prescribing? What is dispensing? Enabling legal frameworks
More informationRegulatory,Quality & Emergency Preparedness. MaryBeth Parache Director, Quality Affairs New York Blood Center
Regulatory,Quality & Emergency Preparedness MaryBeth Parache Director, Quality Affairs New York Blood Center 1 Regulatory 2 Who regulates us? Food and Drug Administration (FDA) Blood, tissue, HCT/P, medical
More informationSOP18b: Standard Operating Procedure for Preparing for External Audit and Inspection
SOP18b: Standard Operating Procedure for Preparing for External Audit and Inspection Authorship Team: Jemma Hughes, Tina Morgan, for Joint SOP Group on Trial Processes (viz Leanne Quinn, Ian Russell, Anne
More informationGuide to Renewal of Veterinary Product Authorisations
Guide to Renewal of Veterinary Product Authorisations AUT-G0024-3 04 JANUARY 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS
More informationMHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager
MHRA Findings Dissemination Joint Office Launch Jan. 2012 Presented by: Carolyn Maloney UHL R&D Manager Purpose of presentation To feed back abridged findings from March 2011 MHRA Statutory Systems Inspection
More informationThe U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements
The U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements Beatrice Moreau Senior Regulatory Advisor Registrar Corp 144 Research Drive Hampton, Virginia USA 23666
More informationMarie-Claire Rickard, RG and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager
Standard Operating Procedures (SOP) for: Pharmacovigilance processing for the JRMO SOP Number: 26c Version Number: V1 Effective Date: 5/8/16 Review Date: 5/8/17 Author: Reviewer: Reviewer: Authorisation:
More informationFood Safety Capacity Building: The role of public private partnerships
Food Safety Capacity Building: The role of public private partnerships Paul Young, PhD Senior Director, Food and Environment Business Operations, Waters Corporation 2011 Waters Corporation 1 Background
More informationAnnual report of the Good Clinical Practice Inspectors Working Group 2016
15 June 2017 EMA/INS/GCP/763873/2016 Committees and Inspections Annual report of the Good Clinical Practice Inspectors Working Group 2016 Adopted by the GCP IWG on 2 June 2017 30 Churchill Place Canary
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Sponsorship SOP-RES-001 Version Number 3 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s) Teresa
More informationGuidance for registered pharmacies preparing unlicensed medicines
Guidance for registered pharmacies preparing unlicensed medicines May 2014 The text of this document (but not the logo and branding) may be reproduced free of charge in any format or medium, as long as
More informationMEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS Memorandum of understanding between MHRA, COREC and GTAC
MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Memorandum of understanding between MHRA, COREC and GTAC 1. Purpose and scope 1.1 Regulation 27A of the Medicines for Human Use (Clinical Trials)
More informationGuidance for the conduct of good clinical practice inspections
23 August 2017 EMA/839541/2015 Guidance for the conduct of good clinical practice inspections Adopted by GCP Inspectors Working Group (GCP IWG) 4 September 2017 Keywords Conduct of GCP inspections 30 Churchill
More informationOverview of the IMB s. Good Clinical Practice. Deirdre O Regan GCP/Pharmacovigilance. GCP Seminar Dublin, 27 th January 2010.
Overview of the IMB s Approach to Inspection of Good Clinical Practice GCP Seminar Dublin, 27 th January 2010 Deirdre O Regan GCP/Pharmacovigilance Inspection Manager Slide 1 Introductions/Organisation
More informationConnie Hoy October 2013
Connie Hoy October 2013 Warning letter issued to firm for complaint handling Failure to report within 30 days Failure to implement adequate procedures Failure to establish standard review process No procedure
More informationThis Agreement dated DD/MM/YYYY (the Effective Date ) is between
Clinical Trial Delegation of Sponsorship Responsibilities to Chief This Agreement dated DD/MM/YYYY (the Effective Date ) is between Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, NG7
More informationICH ASSOCIATION 2016 ANNUAL REPORT
ICH ASSOCIATION 2016 ANNUAL REPORT International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH Secretariat, Chemin des Mines 9, 1202 Geneva, Switzerland Telephone:
More informationVersion Number: 003. On: September 2017 Review Date: September 2020 Distribution: Essential Reading for: Information for: Page 1 of 13
CONTROLLED DOCUMENT Reporting Research Incidents and Breaches Policy CATEGORY: CLASSIFICATION: PURPOSE Controlled Number: Document Policy Governance To set out the framework and principles for reporting
More informationINTERNSHIP AND COMMUNITY SERVICE PLACEMENT HANDBOOK 2018/19
INTERNSHIP AND COMMUNITY SERVICE PLACEMENT HANDBOOK 2018/19 About the handbook This handbook has been developed to help medical interns and community service applicants to apply for the Internship and
More informationUnofficial copy not valid
Page 2 (9) CONTENTS 1. PURPOSE... 3 2. DEFINITIONS... 3 3. RESPONSIBILITY... 3 4. INVESTIGATOR SELECTION... 3 4.1 Identification of Investigator s... 3 4.2 Initial Contacts... 4 4.3 Distribution of Pre-Study
More informationFood Hygiene Rating Scheme A Report for the National Assembly of Wales
Food Hygiene Rating Scheme A Report for the National Assembly of Wales Review of the Implementation and Operation of the Statutory Food Hygiene Rating Scheme and the Operation of the Appeals System in
More informationKeele Clinical Trials Unit
Keele Clinical Trials Unit Standard Operating Procedure (SOP) Summary Box Title Safety Reporting and Pharmacovigilance SOP Index Number SOP 20 Version 4.0 Approval Date 31-Jan-2017 Effective Date 14-Feb-2017
More informationUpdate of the Work plan on international activities 2012
Helsinki, 15 December 2011 Doc.: MB/57/2011 final Update of the Work plan on international activities 2012 (Document endorsed by the Management Board) WORK PLAN FOR INTERNATIONAL ACTIVITIES OF ECHA 2012
More informationMethods: Commissioning through Evaluation
Methods: Commissioning through Evaluation NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning Nursing Trans. & Corp. Ops. Commissioning Strategy
More informationWelsh Government Response to the Report of the National Assembly for Wales Public Accounts Committee Report on Unscheduled Care: Committee Report
Welsh Government Response to the Report of the National Assembly for Wales Public Accounts Committee Report on Unscheduled Care: Committee Report We welcome the findings of the report and offer the following
More informationGovernment takes over TB medicines supply in Moldova: way forward
Government takes over TB medicines supply in Moldova: way forward Rita Seicas Programme Coordinator Center for Health Policies and Studies (PAS Center) Fighting Drug-Resistant TB in the 21st Century: Novel
More informationAddendum to ICH E6 (R2)
Addendum to ICH E6 (R2) Stephanie Shapley (US FDA) - Rapporteur Dr. Fergus Sweeney (EMA) - Regulatory Chair Date: December 15, 2015 International Council for Harmonisation of Technical Requirements for
More information20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central Fax central
SOP 408.4 Annex C 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Contract Research Organization
More informationStandard Operating Procedures
Standard Operating Procedures 5.7 Site Initiation Version V1.0 Author/s Approved B Fazekas, S Kochovska D Currow Effective date 30/09/2017 Review date 30/09/2019 DO NOT USE THIS SOP IN PRINTED FORM WITHOUT
More informationMarie-Claire Rickard, Governance and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager
Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of or the Trial Protocol SOP Number: 037 Version Number: 5.0 Effective Date: 17/6/16 Review Date: 17/6/18 Author: Reviewer: Reviewer
More informationNHS COMMISSIONING BOARD AUTHORITY. Minutes of a Private Meeting held on 13 April 2012
NHS COMMISSIONING BOARD AUTHORITY Minutes of a Private Meeting held on 13 April 2012 Present: Professor Malcolm Grant (Chair) Sir David Nicholson, Chief Executive Mr Ed Smith, Non-Executive Director Mr
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL SECTION 21 APPLICATION FORM Only to be used for orthodox/allopathic medicines for human use. 1. Fax completed form (i.e. pages 1-10), proof of payment of application fee (if applicable)
More information